Agenus Inc. (AGEN) Upgraded at ValuEngine

Agenus Inc. (NASDAQ:AGEN) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Monday, July 24th.

Several other equities research analysts have also commented on AGEN. HC Wainwright set a $5.00 target price on shares of Agenus and gave the stock a “hold” rating in a research report on Saturday, May 6th. Maxim Group restated a “buy” rating and set a $7.00 target price on shares of Agenus in a research report on Sunday, April 23rd. Finally, Zacks Investment Research raised Agenus from a “sell” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.88.

Agenus (AGEN) traded up 1.71% during trading on Monday, reaching $3.57. 483,682 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $4.25 and a 200 day moving average price of $3.90. Agenus has a 52 week low of $3.20 and a 52 week high of $7.49. The firm’s market capitalization is $355.97 million.

Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.04. The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $6.66 million. Agenus had a negative net margin of 280.96% and a negative return on equity of 37,577.49%. The business’s revenue was down 36.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.33) EPS. Equities research analysts forecast that Agenus will post ($1.13) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC increased its position in shares of Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 23,689 shares during the last quarter. OxFORD Asset Management LLP bought a new position in Agenus during the second quarter worth approximately $141,000. AQR Capital Management LLC bought a new position in Agenus during the fourth quarter worth approximately $143,000. Voya Investment Management LLC increased its position in Agenus by 18.5% in the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after buying an additional 6,381 shares in the last quarter. Finally, American International Group Inc. increased its position in Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,984 shares in the last quarter. 41.54% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply